secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-02-07T23:59:59+00:00
Accession:  0001601830-24-000012
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Recursion Pharma CBO Virani transitions to Senior Strategic Advisor; Kinn joins exec team
--------------------------------------------------------------------------------

- Dr. Shafique Virani stepped down as Chief Business Officer effective Feb 6, 2024, to become Senior Strategic Advisor.
- Matthew Kinn, previously SVP Business Development, assumes all CBO responsibilities on Recursion's executive team.
- Virani receives advisory fees of $1,000/hour (min $25k/month Feb–Jul, then $15k/month) and continued equity vesting.
- If terminated before Aug 1, 2024, Virani gets a lump sum starting at $390k (Feb) decreasing $65k/month.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000012/0001601830-24-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000012/rxrx-20240206.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer